Pancreatic ductal adenocarcinoma (PDAC) is one of the malignant lethal tumors. It has been reported that the transcriptional regulator Yin Yang-1 (YY1) suppressed the invasion and metastasis of PDAC. However, the function of YY1 on proliferation and migration of pancreatic cancer remains to be clarified. In this study, we found that YY1 overexpression or knockdown can inhibit or promote the proliferation and migration of pancreatic cancer cells. Digital gene expression sequencing indicates that cyclin-dependent kinase inhibitor 3 (CDKN3) may be the candidate target gene of YY1. Then we found that YY1 can downregulate the expression of CDKN3 by directly binding to the promoter region of CDKN3. Silencing CDKN3 expression could inhibit the ability of cell proliferation and migration and overexpression of CDKN3 could restore the effects induced by YY1 overexpression in pancreatic cancer cells. The expression levels of YY1 and CDKN3 were negatively correlated in pancreatic cancer tissues and PDAC patients with higher levels of CDKN3 have poor prognosis. Vitro and vivo study show that CDKN3 can form a complex with MdM2-P53, thus leading to inhibiting the expression of P21, which is the target gene of P53, and finally facilitates the cell cycle to promote the proliferation of pancreatic cancer cells. Hence, YY1 can directly regulate the expression of CDKN3 and participate in the cycle of pancreatic cancer cells, which can inhibit the progression of pancreatic cancer. These results reveal that YY1-CDKN3-MDM2/P53-P21 axis is involved in pancreatic tumorigenesis, which may develop new methods for human pancreatic cancer therapy.
Pancreatic cancer is a malignant tumor with poor prognosis, of which mortality is close to morbidity, and 5-year survival rate is only 8%. 1 Most of the pancreatic cancer patients are diagnosed at an advanced stage, with a 5-year survival rate of 3%. 1 Because of the early postoperative recurrence of pancreatic cancer and the resistance to radiotherapy and chemotherapy, there is no particularly good method for the treatment of pancreatic cancer. 2, 3 In addition, the molecular mechanism of pancreatic tumorigenesis remains unknown. Therefore, there is an urgent need to gain insight into the biological mechanism that involves in the development and progression of pancreatic cancer to develop effective therapies. Yin Yang-1 (YY1) is a conserved multifunctional protein belonging to the GLI-Kruppel family, and it binds to the promoter of other genes mainly through the C terminal zinc finger region. [4] [5] [6] As a transcriptional regulator, YY1 is involved in multiple biological functions of cells including embryonic formation, cell proliferation, apoptosis, DNA repair and differentiation by regulating the expression of different genes. 7, 8 Just like its name "Yin Yang" indicates, YY1 can function as an activator or as a repressor to regulate the expression of different genes based on its interacting proteins and cell types. 6 It has been reported that YY1 is overexpressed in many tumors, such as breast, ovary, colon, prostate and gastric cancer. [9] [10] [11] [12] [13] Moreover, YY1 acts as the inhibitory role in many tumors. [10] [11] [12] From our previous studies, we found that YY1 was also highly expressed in pancreatic cancer and acted as a tumor suppressor, which inhibited cell invasion and metastasis by downregulating MMP10 expression or increased cell apoptosis by activating Bax. 14, 15 It has been reported that YY1 has an effect on the proliferation of tumor cells (such as breast carcinoma cells, glioblastoma cells) and plays an inhibitory role. 16 However, the effect of YY1 on the proliferation of pancreatic cancer remains unclear.
Cyclin-dependent kinase inhibitor 3 (CDKN3) is a member of the protein phosphatase family and plays an important role in the regulation of cell cycle. 17, 18 Interestingly, CDKN3 also has two sides that can be combined with CDK2, blocking the synthesis of G1/S protein to inhibit cell cycle, or forming a complex with MDM2-P53, then inhibits the expression of P21 to facilitate cell cycle. [19] [20] [21] Therefore, CDKN3 may play a role in inhibiting or promoting cancer progression. Overexpression of CDKN3 has been discovered in breast, 22 prostate, 22 ovary, 23 glioblastoma, 24 liver 25 and renal cancers. 26 However, to our best of knowledge, the study of CDKN3 in pancreatic cancer has not been reported. Therefore, it is necessary to further investigate the molecular mechanism of CDKN3 in pancreatic cancer.
In this study, we found that overexpression of YY1 could inhibit the proliferation and migration of pancreatic cancer cells and CDKN3 is a direct and functional target of YY1. In addition, we demonstrated that YY1 suppresses proliferation and migration of pancreatic cancer by regulating the CDKN3/MdM2/P53/P21 signaling pathway.
Material and Methods

Cell lines, cell culture and reagents
Human pancreatic ductal adenocarcinoma (PDAC) cell lines BXPC-3 and PANC-1 were acquired from the Shanghai Cell Bank (Shanghai, China). Previously, the stable cells of YY1 overexpression or knockdown were already constructed in BXPC-3 and PANC-1 cell lines, and the stable cell lines (BXPC-3-Vector, BXPC-3-YY1, BXPC-3-Scramble shRNA, BXPC-3-YY1 shRNA, PANC-1-Vector, PANC-1-YY1, PANC-1-Scramble shRNA and PANC-1-YY1 shRNA) were selected by culturing in media containing 5 lg/ml puromycin (Sigma, St Louis, MO).
14,15 YY1 expression was confirmed by
qRT-PCR and Western blot. The cells were cultured in Dulbecco's modified Eagle's medium (Life Technologies) supplemented with 10% fetal bovine serum (Wisent, Montreal, QC, Canada), 10 mM HEPES (Sigma, St Louis, MO), 2 mM L-glutamine (Sigma), 1 mM pyruvate sodium (Sigma), 100 units/ml penicillin (Life Technologies) and 100 lg/ml streptomycin (Life Technologies) at 378C in a humidified atmosphere containing 95% air and 5% CO 2 .
Transfection of siRNAs and plasmids
The specific small interfering RNAs (siRNAs) for CDKN3 were purchased from Shanghai GenePharma, and the siRNA sequences were listed in Supporting Information Table S1 . The human CDKN3 overexpression pCMV3-CDKN3 vectors were obtained from Obio Technology (Shanghai; Plasmid#: H4465) and CDKN3 plasmids sequences were listed in Supporting Information Table S2 . The transfection of siRNA and plasmid was performed according to the Lipofectamine3000 (Life Technologies) specification. The expression of CDKN3 was proved by qRT-PCR and Western blot.
Preparation of CDKN3 overexpression cells
CDKN3 overexpression lentiviruses were constructed by Obio Technology (Shanghai) Corp. Ltd. Briefly, the fulllength coding region of human CDKN3 was subcloned into the pLenti-EF1a-mcherry-P2A-Neo-CMV-CDKN3-3Flag vector (System Biosciences, Mountain View, CA) and verified by sequencing (Supporting Information Table S2 ). The verified recombinant vector and the pPACKH1 packaging plasmid mix (System Biosciences) were co-transfected into 293 T cells using the Lipofectamine 3000 reagent. The supernatant of the cultured 293 T cells was collected to infect PANC-1 cells and PANC-1-YY1 cells. The pLenti-EF1a-mcherry-P2A-Neo-CMV-3Flag vector was used to package the virus and infect PANC-1 cells and PANC-1-YY1 cells as a control. Stable cell lines were selected by culturing in media containing 500 lg/ ml G418 (neomycin sulfate). CDKN3 expression was confirmed by qRT-PCR and Western blot.
What's new?
The molecular mechanisms of pancreatic tumorigenesis remain unknown. This study demonstrates that high expression of YY1 inhibits the proliferation and migration of pancreatic cancer cells by downregulating CDKN3 expression. Thus, YY1 negatively regulates the expression of CDKN3 by directly binding to the CDKN3 promoter region and the reduction of CDKN3 expression decreases the formation of complexes with MDM2-P53, which upregulates the expression of P21 and suppresses the proliferation of pancreatic cancer cells. The results reveal that the YY1-CDKN3-MDM2/P53-P21 axis is involved in pancreatic tumorigenesis, which may pave the way for the development of new methods for human pancreatic cancer therapy.
Total mRNA extraction and quantitative real-time RT-PCR
According to the instructions of mRNA extraction, the cells were dissolved in TRIzol reagent (Invitrogen) to extract the total mRNA. After spectrophotometric quantification, cDNA was synthesized using iScript cDNA Synthesis Kit (Bio-Rad) based on its operating instructions. Quantitative real-time RT-PCR was done using SYBR green reagent (Life Technologies) in a Step One Plus Real-time PCR System (Thermo Fisher Scientific) according to the manufacturer's protocol. The sequences of the primers are listed in the Supporting Information Table S3 . The target gene expression of YY1 and CDKN3 were calculated by the comparative delta CT (2 -DDCt ) method and standardized the expression using b-actin, which sequences were listed in Supporting Information Table  S3 . Each quantitative PCR was performed in triplicate and independently repeated three times.
Western blotting
Total cells were lysed with RIPA lysis buffer and collected as described previously. 27 Protein concentrations were measured in the DC protein assay kit (Bio-Rad). Protein was electrophoresed on the 8-12% SDS-PAGE, transferred into the PVDF membrane, blocked in 5% nonfat dry milk in 0.1% Tween 20 (TBST) buffer at room temperature for 2 h, incubated in fresh blocking buffer with primary antibodies for 48C overnight, the membrane was washed and then incubated with HRP-conjugated secondary antibodies for 2 h at room temperature. The strips were washed again and then visualized with Immobilon Western Chemilum HRP substrate (Merck Millipore, Darmstadt, Germany) using the Fluorchem E System (ProteinSimple, Santa Clara, CA), as previously described. 27 Anti-p53, anti-p53 (phosphor Ser15) and anti-p21 were purchased from Cell Signaling Technology (Danvers, MA). Anti-MDM2 (ab#178938), anti-MDM2 (phosphor S166) (ab#170880), anti-CDKN3 (ab#127986) and anti-YY1 (#ab12132) for ChIP were obtained from Abcam (Cambridge, MA). Anti-b-actin was purchased from Vazyme (Nanjing, China). Each blot was independently repeated three times.
Cell count kit-8 and EdU assay for cell proliferation
To detect cell proliferation, we used the CCK-8 assay kit (DOJINDO, Japan) and Cell Light EdU DNA imaging Kit (RiboBio, Guangzhou, China), according to the manufacturers' protocol. For the CCK-8 assay, cells were seeded into 96-well plates at 2 3 10 3 /well. At the same time of each day, 10 ll CCK-8 was added to each well, which contained 100 ll medium. After incubation for 3 h, the absorbance at 450 nm of each well was measured using a microplate reader. For the EdU incorporation assay, cells were seeded into 96-well plates at 53 10 3 /well. After 48 h of incubation, 100
ll EdU (50 lM) was added to each well and incubated for 2 h. The cells were then fixed with 4% paraformaldehyde for 30 min and permeabilization with 0.5% Triton X-100 for 10 min, followed by EdU staining with Apollodyeing reaction for 30 min. At last, the DNA was stained with Hoechst 33342 for 30 min, and the proportion of nucleated cells dyeing EdU was observed by fluorescence microscopy. Each sample had five duplicate wells and was independently repeated three times.
Flow cytometry assay
The cell cycle was revealed by flow cytometry assay, using Cell Cycle Analysis kit (Beyotime, Shanghai, China), according to the manufacturer's protocol. After 48 h of transfection, the cells were digested and washed with phosphate buffer saline for three times and then fixed in the 70% alcohol for 2208C >12 h. The fixed cells were washed three times as before, and then stained with propidium iodide (PI) dyeing buffer, which contained 200 lg/ml RNase and 50 lg/ml PI at room temperature for 30 min away from light. Analysis of the cell cycle were performed by flow cytometer (LSR, BD Biosciences). The experiment was repeated three times.
Wound healing assay and transwell assay
Cell migration ability was evaluated by the wound healing assay and transwell assay. For wound healing assay, 48 h after transfection, the cells in 6-well plates were fused together, and the monolayer was scratched with a sterile 20 ll pipette tip, washed with PBS to remove the floated and detached cells and photographed (time 0 and 48 h) by inversion fluorescence microscope (Olympus, Japan).The relative wound areas were then measured using Image J software. For transwell assay, 24 well Millicell Hanging Cell Culture Inserts (PET membranes with 8 lm pores, Merck Millipore) were used; 5 3 10 4 cells were seeded in the upper chamber and culture medium containing 10% serum was used in the lower room as a chemoattractant to induce the cells migrate to the other side of the membrane. After 24 h of culture, nonmigrating cells were removed from the upper surface of the membrane by wiping with cotton-tipped swabs. Cells on the lower surface of the membrane were stained with 0.1% crystal violet for 20 min and photographed. For invasion assays, the upper surface of each insert was covered with Matrigel (BD Bioscience Pharmingen), in accordance with manufacturer's protocol. After 48 h of incubation, the rest of the procedure was the same as the Migration Experiment. All experiments were repeated three times.
Digital gene expression (DGE) sequencing
Total RNA extracting from BXPC-Scramble shRNA and BXPC-YY1 shRNA cells were prepared as described previously.
14 Quality and quantity analysis of total RNA, DGE library preparation and sequencing were performed at Huada Genomics (Shenzhen, China). The specific operation of the DGE was documented in our previously published articles. 14 We conducted two biological replicates of the DGE sequencing and took the average of the two before differential gene expression analysis. For gene expression profiling analysis, we performed gene ontology (GO) enrichment analysis for functional significance using a hypergeometric test to map all DEGs to terms in GO database, looking for significantly enriched GO terms in DEGs compared with the genome background.
Patients and pancreatic tissues
The specimens of pancreatic tissue were derived from 32 patients who underwent pancreaticoduodenectomy for pancreatic cancer at the first Affiliated Hospital of Nanjing Medical University, China, between 2006 and 2012. No chemotherapy or radiotherapy was performed before tumor removal. All patients signed informed consent for the use of clinical specimens for research and the Ethics Committees of the first Affiliated Hospital of Nanjing Medical University approved the study. Each tissue sample was cut into two parts immediately (within 5 min) upon surgical removal, one was snap-frozen in liquid nitrogen until use and the other was fixed in 5% formalin and embedded in paraffin after 24 h. The pathology of all tissue specimens was diagnosed by pathologists. The 32 patients were followed up regularly until 31 May 2013. Patients' overall survival was defined as the time between surgery and death or the last follow-up date. None of the 32 selected patients died within one month after surgery.
Construction of reporter gene plasmids
A luciferase reporter construct containing the human CDKN3 promoter (-1000/-1, upstream of translation initiation sites, TIS) was prepared using the pGL3-basicvector (Promega, Madison, WI). A DNA fragment of the CDKN3 promoter region (including restriction enzyme sites) synthesized by GenScript Biotechnology (Nanjing, China) was subcloned into the KpnI and XhoIsites of the pGL3-basic vector to construct the pGL3-CDKN3-promoter (pCDKN3) recombinant plasmid, which was confirmed by sequencing. The mutant construct pCDKN3-YY1-M, containing the CDKN3 promoter in which the presumed YY1 binding site (nucleotides-393/-384) was mutated from ATCCTGCCAT to ATCCTATTCG, was also constructed.
Dual-luciferase reporter assay
The reporter gene plasmid has been constructed as described above, and transfections were performed using Lipofectamine 3000 according to the manufacturer's protocol. For luciferase activity assay, the experiment was performed as described previously. 14, 15 Renilla luciferase reporter vector pRL-SV40 was used as an internal control (Promega, Madison, WI) and its luciferase activity were normalized to firefly luciferase activity. 48 h after transfection, cells were lysed for 30 min using 13 passive lysis buffer. Next, Firefly and Renilla luciferase activities were measured with Promega Dual-Luciferases Reporter Assay Kit (PromegaE1980) according to the published protocol. Each experiment was performed in triplicate and independently repeated three times.
Nuclear protein extraction and electrophoretic mobility shift assay (EMSA)
Nuclear extracts were isolated from YY1 overexpressing BXPC-3 cells with NE-PER Nuclear and Cytoplasmic Extraction Reagents (ThermoFisher Scientific) according to the manufacturer's instructions. Protein concentrations were determined with the DC Protein Assay kit. Nuclear extracts were stored at 2808C until use. EMSA was performed using the DIG Gel Shift Kit (Roche) according to the manufacturer's protocol. The sense probe sequences for EMSA were as follows: wild-type probe, 5
0 -ATCCTGCCATCAAGAA GCAA-3 0 , corresponding to nucleotides 2499 to-480 of the CDKN3 promoter; mutant probe, 5
0 -ATCCTATTCGCAA GAAGCAA-3 0 . Double-stranded (ds) probes were synthesized, and the 3 0 -end of the wild-type probe was labeled with digoxigenin-11-ddUTP. Nuclear extracts (5 lg protein) were incubated with 1 lg poly [d(I-C)], the binding buffer included in the kit and DIG labeled wild-type probe in the presence or absence of unlabeled probe for 15 min at room temperature. Bound DNA complexes were separated by 5% nondenaturing polyacrylamide gel electrophoresis and transferred to a nylon membrane (Roche). The nylon membranes were cross-linked, and chemiluminescent detection was performed using CSPD. Signals were recorded using the Fluorchem E System. In supershift analyses, the YY1 antibody (4 lg; Abcam) was added to nuclear extracts in gel shift buffer (above) for 1 h at 48C, followed by addition of the probe. The subsequent protocol steps were the same as above.
Chromatin immunoprecipitation assay (ChIP)
ChIP analysis was performed using the EZ ChIP kit (Merck Millipore) according to the manufacturer's instructions with some modifications as the published protocol. 15 The final purified DNA fragment was subjected to PCR analysis using Hot-Start Taq DNA polymerase (Takara, Dalian, China; 32 cycles). The primers used were as follows: sense CGAGAC-CAGCCTGACCAACA, antisense CTTCCAGCAACCAAT-CAGAT (product length 290 bp). PCR products were analyzed using gel electrophoresis.
Animal study
Four-week-old male nude mice (BALB/cA-nu) were purchased from the Animal Center of Nanjing Medical University. The stable cells (BXPC-3-YY1-CDKN3, BXPC-3-YY1, BXPC-3-vector and PANC-1-YY1-CDKN3, PANC-1-YY1, PANC-1-vector) were prepared as described previously. A group of five mice and a total of six groups were used to establish xenograft subcutaneous implant tumor model. The stable cells were injected into the blank area of the bilateral forelimb in nude mice (1.5 3 10 6 cells/100 ll per flank),
individually. Waiting until the tumor is visible, the tumor size was measured with caliper every week. The tumor volume was calculated using the formula (width 2 3 length)/2.
Statistical analysis
Statistical analysis was performed using the SPSS software (Version 22.0) and Graphpad Prism (Version 5.0). Quantitative data are presented as mean 6 SD. Differences in the mean of two samples were analyzed by Student's t test. Counting and calculating area was executed with Image-Pro Plus 6.0. All statistical tests were considered significant when *p < 0.05, **p < 0.01, or ***p < 0.001.
Results
YY1 suppresses the proliferation and migration of PANC-1 cells and BXPC-3 cells in vitro
To elucidate the effects of overexpression or knockdown of YY1 on the proliferation of pancreatic cancer cells, we investigated the effect of YY1 on cell proliferation by CCK8 and EdU assays. Figures 1a and 1b showed the CCK8 assays' results. YY1 overexpression significantly decreased the absorption of BXPC-3 and PANC-1 cells in OD450 compared with the control group. In contrast, YY1 knockdown increased the absorbance value of pancreatic cancer cells at OD450. Furthermore, we further employed the EdU experiments to prove that YY1 suppresses the proliferation in BXPC-3 and PANC-1 cells. As shown in Figures 1c and 1d , the proportion of EdU-positive nuclei was significantly decreased in BXPC-3-YY1 and PANC-1-YY1 cells, while ectopic YY1 had the opposite effect. For flow cytometry assay, we found that the cell cycle distributed in G0-G1 phase of PANC-1-YY1 was significantly higher than that in control group (Fig. 1j) . Conversely, the proportion of pancreatic cancer cell cycle in the G0-G1 phase of BXPC-3-YY1 shRNA was less than that in the control group (Fig. 1l) . These results suggested that YY1 overexpression might inhibit the proliferation of pancreatic cancer cells. The transwell migration assays revealed that YY1 overexpression suppressed the migration in BXPC-3 and PANC-1 cells, while YY1knockdown significantly promoted the cells migration abilities (Figs. 1e and 1f) . In addition, the woundhealing assays proved that the overexpression of YY1 in pancreatic cancer cells was slower than that in the control group, whereas silencing YY1 had the opposite effect (Figs. 1g and  1h) . Two experiments are consistent that YY1 overexpression suppressed the migration of the pancreatic cancer cells.
YY1 inhibits the proliferation and migration of pancreatic cancer cells by downregulating CDKN3 in vitro
In order to determine whether the activation of CDKN3 is the key for YY1 to participate in the proliferation and migration of pancreatic cancer cells, siRNAs (siRNA#1, siRNA#2, siRNA#3) and plasmids were used to interfere or upregulate the CDKN3 expression in BXPC-3, PANC-1 or YY1 stable cells and the CDKN3 expression was showed in Figure 2a and Supporting Information Fig. S1 . Firstly, we investigated the proliferation and migration of pancreatic cancer cells when CDKN3 was overexpressed in BXPC-3 and PANC-1 cells, and found that the proliferation and migration were enhanced in CDKN3-overexpressed cell lines (Figs. 2b and  2d-2g) . We also found that the proliferation and migration abilities inhibited by YY1 overexpression were most recovered by upregulating the expression of CDKN3 (Figs. 3a-3f and Supporting Information Fig. S2) . Moreover, the effect of CDKN3 overexpression on the cell cycle of pancreatic cancer was also investigated. As shown in Figure 2c and Supporting Information Fig. S3 , the percentage of PANC-1-pCMV-CDKN3 cells in S phase was higher than that of control group, that is, CDKN3 overexpression promoted pancreatic cancer cells to enter S phase from G0-G1 phase. Similarly, we selected the most interfered siRNA#2 to knock down CDKN3 expression and si-CDKN3 significantly reduced pancreatic cancer cells proliferation and migration abilities (Supporting Information Fig. S4 ). These results revealed that CDKN3 was a functional target of YY1 and YY1 inhibited the proliferation and migration of pancreatic cancer cells by downregulating CDKN3 in vitro.
Correlation between YY1 and CDKN3 mRNA expression in pancreatic cancer tissues We further found that the level of YY1 was inversely correlated with the level of CDKN3 expression in pancreatic cancer tissues (Fig. 4a) . Quantitative RT-PCR analysis showed that this correlation was statistically significant among the 32 specimens (Fig. 4a, r 5 20 .617, p < 0.001). These results suggested that the expression of CDKN3 was regulated by YY1 in vivo.
Correlation between CDKN3 expression and patient survival
Thirty-two pancreatic cancer patients were enrolled in the survival analysis. Twenty-five patients died, while the remaining seven were alive at the last follow up (31 March 2013). To determine cut-off value of the CDKN3 expression level for survival analysis, the patients were divided into two groups: short-term survivors (survival period < 24 months) and long-term survivors ( 24 months). The threshold value of 0.00594 was chosen as the cut-off value for high and low CDKN3 expression, because 0.00594 [within 95% confidence interval (CI), 0.004-0.013, of CDKN3 mRNA expression] was on the receiver operating characteristic (ROC) curve closest to (0.0, 1.0). This cut-off value maximized both sensitivity and specificity for the survival outcome (Fig. 4b) . The area under the ROC curve (AUC) was 0.797 (95% CI, 0.613-0.981, p 5 0.013).
Kaplan-Meier survival curves showed that patients with high CDKN3 expression (0.00594) had lower postoperative survival than those with low expression (<0.00594; Fig. 4c , p 5 0.017, log rank test). These results indicate that higher expression of CDKN3 predicted bad outcome in pancreatic cancer patients.
YY1 negatively regulates the expression of CDKN3 in pancreatic cancer cell lines
To understand the mechanism of YY1 on the proliferation and migration of pancreatic cancer, DGE-seq was performed to predict the potential target genes of YY1 using BXPCScramble shRNA and BXPC-YY1 shRNA cells. CDKN3 was selected as a potential target gene of YY1 and involved in cell cycle and cell migration of pancreatic cancer cells. Additionally, we demonstrated that YY1 negatively regulated CDKN3 expression by PCR and Western blotting. As shown in Figures 5a and 5b, CDKN3 mRNA and protein were downregulated in BXPC-3-YY1 and PANC-1-YY1 compared with control group. Correspondingly, CDKN3 mRNA and protein expression was upregulated while YY1 was downregulated in BXPC-3 and PANC-1 (Figs. 5a and 5b) . These results, in combination with those of the in vivo experiments, further supported that YY1 may negatively regulate the expression of CDKN3, thereby inhibiting the proliferation and migration of pancreatic cancer.
YY1 directly binds to the promoter region of CDKN3 and activate its expression
To make evidence that YY1 binding to the promoter region of CDKN3 can trigger the expression of CDKN3, CDKN3 reporter gene plasmids and its mutant plasmids were constructed to perform luciferase activity assay (Fig. 5c ). YY1 overexpression plasmid and reporter gene plasmid were cotransfected into BXPC-3 and PANC-1 cells. As shown in Figure 5d , YY1 overexpression significantly reduced the fluorescence value compared with the value of vector cells.
Additionally, the fluorescence activity of YY1 overexpression cells transfected with plasmids for predicting binding site mutation was drastically increased (Fig. 5d) . These results indicated that YY1 could activate the transcription of CDKN3.
To prove that YY1 can directly bind to the promoter region of CDKN3, we verified the results in vivo and in vitro using EMSA and ChIP, respectively.
For the EMSA assay, we first extracted the nuclear protein from BXPC-3-YY1 cells, and then designed and synthesized the nucleic acid probe near the promoter region (nucleotides 2499 to 2480). The results displayed in Figure 5a , lane 2 represented the complex formed by a labeled probe and nuclear protein reaction and showed a slower migration. The competitive reaction showed that the formation of the complex was inhibited with increasing amount of unlabeled probes (Fig. 5e lane 3-4) . However, the inhibitory effect of the mutant probes on the formation of the complex was decreased obviously (Fig. 5e lane 5-6 ). In super-shift reaction, the lane 7 appeared a specific DNA-protein complex which was super shifted by adding YY1 antibody and the DNA-protein complex of lane 8 which adding IgG antibody has not been observed super-shifting reaction (Fig. 5e lane  7-8) .
ChIP assay was performed to further confirm that YY1 could bind to the promoter region of CDKN3 in vivo. The purified DNA by YY1-antibody was prepared from the cells (BXPC-3-YY1, BXPC-3-vector) as described above. The input reserved in advance for proving that a specific promoter region of DNA was present. The PCR results using the primers for the CKDN3 promoter region that YY1 bind to were shown in Figure 5b . Two cell lines showed that the bands of YY1 overexpression were significantly higher than their control group (Fig. 5f) . These results strongly suggested that YY1 could directly bind to the promoter region of CDKN3 in vivo and in vitro.
YY1 inhibits the growth of pancreatic cancer by downregulating CDKN3 in vivo
The stable cells (PANC-1-YY1 1 CDKN3, PANC-1-YY1, PANC-1-vectorand PANC-1-CDKN3 and CDKN3-vector) were prepared as described above and CDKN3 expression was verified by PCR and Western blotting as shown in Supporting Information Fig. S5 . The stable cells were injected subcutaneously into BALB/cA-nu nude mice respectively. When the tumor is visible to the naked eye, we measured the size of the growing tumors with caliper weekly for four weeks. The results showed that the tumor size which formed by PANC-1-CDKN3 cells were significantly bigger than the control group in tumor size (Fig. 6a) . The tumor sizes of the PANC-1-YY1 were significantly smaller than the PANC-1-vector group, while the tumor sizes of PANC-1-YY1 1 CDKN3 group were almost the same as the PANC-1-vector group (Fig. 6b) . All data of tumor sizes and average weight of tumors were drawn with line graph (Figs. 6a-6d) . In vivo study, the results also indicated CDKN3 was a functional target of YY1 and YY1 inhibited the growth of pancreatic cancer by downregulating CDKN3 in vivo.
YY1 regulates MdM2/P53/P21 signaling pathway via CDKN3
To further understand the mechanism of how YY1 inhibited the proliferation of pancreatic cells through downregulating CDKN3, the cell cycle-associated proteins (MdM2, P53, P21) were detected by Western blotting. As showed in Figures 6e and 6f, the total MdM2 and P53 proteins and their phosphorylated proteins were invariant in BXPC-3-YY1 and PANC-1-YY1 cells compared to the control group cells, while the level of P21 protein in YY1 overexpression cells was higher than the YY1 overexpression control groups (Figs. 6e  and 6f) . However, the expressions of P21 protein were downregulated when upregulating the CDKN3 expression in BXPC-3-YY1 and PANC-1-YY1 cells. All data showed that overexpression of YY1 could inhibit the P53-P21 pathway by down regulating the expression of CDKN3, which resulted in suppressing the proliferation of pancreatic cancer cells. Just as mentioned in the previous articles, 21, 28 CDKN3 could form complexes with MdM2 and P53 to inhibit the protein expression of P21, which is the target gene of P53. All in all, YY1 suppressed proliferation and migration of PDAC by regulating the CDKN3/MdM2/P53/P21 signaling pathway.
Discussion
YY1 has been reported to be highly expressed in different types of tumors and act as a significant regulator in oncogenesis. 8 At present, whether YY1 is a tumorigenesis or a tumor suppressor in cancers is still controversial. 29 As its name suggests, YY1 act as activator or inactivator relying on its interacting partners. YY1 acted as tumorigenesis in tumors, when it up-regulated expression of oncogenes (c-Myc,VEGF) or downregulated expression of antioncogenes (P53).
30-32 YY1 acted as a tumor suppressor, when it upregulated expression of antioncogenes(HLJ1,BRCA1) or down-regulated expression of oncogenes(c-Myc) by forming complex with other repressors. [33] [34] [35] According to our previous study, YY1 is highly expressed and plays the role of a tumor suppressor factor in pancreatic cancer. 14, 15 It has been found that high expression of YY1 can inhibit the invasion and metastasis and promote the apoptosis in pancreatic cancer cells. 14, 15 In this study, we reveal that YY1 suppresses the abilities of proliferation and migration in pancreatic cancer cells, which is consistent with the anticancer role of YY1in pancreatic cancer. This lays a solid foundation for further studying definite regulatory mechanism of YY1 in pancreas tumorigenesis.
Our previous work showed that YY1 downregulates MMP10 to inhibit the invasion and metastasis of pancreatic cancer and activates Bax expression to promote the apoptosis in PDAC. 14, 15 This study showed that YY1 could reduce the proliferation and migration of pancreatic cancer cells by downregulating the expression of CDKN3. CDKN3 can affect the proliferation of cells as an important regulatory gene in the cell cycle pathway. Recently, more and more reports have revealed that CDKN3 acts as a tumorigenesis in various types of tumors, such as breast, 22 prostate, 22 ovary, 23 glioblastoma 24 and liver 25 and renal cancers. 26 Although the role of CDKN3 in many tumors has been reported, its specific function is not uniform and the current report focuses on its effects on tumor cell proliferation and migration. [24] [25] [26] The role of CDKN3 in pancreatic cancer has not been explored so far. Meanwhile, our previous DGE-sequencing analysis showed that among the 136 genes upregulated in YY1 knockdown BXPC-3 cells, one of the genes, named CDKN3, was upregulated by 2.4-fold. 14 Interestingly, our group found that YY1 negatively regulated the expression of CDKN3 and we further verified the same results in BXPC-3 and PANC-1 cells using PCR and Western blotting, respectively. The expression levels of YY1 and CDKN3 in pancreatic cancer tissues were inversely correlated, which further demonstrated that YY1 negatively regulated the expression of CDKN3. Moreover, CDKN3 was able to significantly recover the proliferation and migration ability of YY1 overexpressed pancreas cancer cells. It has been reported that CDKN3 was identified as MDM2-interacting protein to repress its specific target gene and CDKN3 could interact with P53 protein. 36 As indicated in previous study, CDKN3 formed a stable complex with MDM2 and P53, CDKN3-MDM2-P53 complex, in cells. 21, 28 Furthermore, P53, which targeting the P21, can induce the cell growth by blocking the cell cycle and the cell cycle would be arrested in G0-G1 phase when the P53-P21 signaling pathway is activated. [37] [38] [39] [40] Our study found that the cell cycle was arrested at G0-G1 phase when YY1 was overexpressed in pancreatic cells, and CDKN3 overexpression notably facilitated the cell cycle into S phase through interacting with MdM2-P53 to downregulate the expression of P21 in pancreatic cancer cells. The decrease of P21 expression leads to cell cycle into S phase, which is DNA synthesis stage, and its proportion represents cell proliferation ability. [41] [42] [43] Namely, CDKN3 could reverse the effect of overexpression of YY1 on pancreatic cancer cell cycle arrest to promote the pancreatic cancer growth. The molecular mechanism is based on the direct binding of YY1 to the promoter region of CDKN3 and activation of its transcription.
YY1 is apparently able to initiate transcription of CDKN3. Our EMSA and ChIP experiments strongly demonstrated that YY1 could directly bind to the predicted YY1 binding site in the CDKN3 promoter region both in vivo and in vitro. Double luciferase assay showed that overexpression of YY1 could decrease the activity of the CDKN3 promoter. These results further signified that CDKN3 was an important gene involved in inhibiting the proliferation and migration of pancreatic cancer cells by YY1.
In summary, our study demonstrate that high expression of YY1 inhibits the proliferation and migration of pancreatic cancer cells by downregulating CDKN3 expression. Besides, the molecular mechanism is that YY1 negatively regulates the expression of CDKN3 by directly binding to CDKN3 promoter region and the reduction of CDKN3 expression decreases the formation of complexes with MDM2-P53, which upregulates the expression of P21; then suppresses the proliferation of pancreatic cancer cells. Although there are unknown mechanisms that may be involved in the biological behavior of YY1 in inhibiting tumor progression, our current studies elucidate that YY1-CDKN3-MDM2/P53-P21 axis participates in suppressing the proliferation and migration of pancreatic cancer cells and may be used as a potential target to develop new treatment agents for pancreatic cancer. 
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